Open AccessAnalysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis
Author(s) -
Jessica M. Fogel,
Donald R. Hoover,
Sun Woo Jin,
Lynne Mofenson,
Mary Glenn Fowler,
Allan W. Taylor,
Newton Kumwenda,
Taha E. Taha,
Susan H. Eshleman
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328344fedc
Subject(s) - nevirapine , zidovudine , medicine , human immunodeficiency virus (hiv) , virology , reverse transcriptase inhibitor , sida , oncology , viral disease , antiretroviral therapy , viral load
In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP + ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis.